Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORINYL 1+50 21-DAY vs DHIVY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Norinyl 1+50 21-Day contains norethindrone (a progestin) and mestranol (an estrogen). Mestranol is converted to ethinyl estradiol, which provides negative feedback on gonadotropin release, inhibiting ovulation. Norethindrone suppresses gonadotropins and alters cervical mucus and endometrial lining to prevent implantation.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Prevention of pregnancy
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
One tablet (1 mg norethindrone + 0.05 mg mestranol) orally once daily for 21 days, followed by 7 placebo tablets. Start on day 1 of menstrual cycle or first Sunday after onset.
DHIVY is not a recognized drug. No dosing information available.
Norethindrone: 5-8 hours; Ethinyl estradiol: 7-15 hours; steady-state reached within 5-7 days
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when Cr Cl <30 m L/min).
Mestranol is demethylated to ethinyl estradiol; ethinyl estradiol and norethindrone are metabolized by CYP3A4. Conjugation (glucuronidation and sulfation) occurs in the liver and gut wall.
Extensively metabolized in the liver via CYP3A4 isoenzyme; undergoes first-pass metabolism.
Renal (40% as metabolites), fecal (50% as metabolites), <1% unchanged
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Norethindrone: ~80% bound to SHBG and albumin; Ethinyl estradiol: ~97% bound to albumin, 2-3% free
98% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
Norethindrone: Vd approximately 4 L/kg; Ethinyl estradiol: Vd approximately 2.5 L/kg; indicates extensive tissue distribution
0.35 L/kg (range 0.3–0.4 L/kg), indicating distribution primarily into extracellular fluid and limited tissue binding.
Oral: Norethindrone ~90%; Ethinyl estradiol ~97-98% (due to low first-pass metabolism)
Oral bioavailability is 60% (range 55–65%) due to first-pass metabolism. Not administered via other routes except IV (100% bioavailability).
No dosage adjustment required for mild-to-moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of fluid retention and hyperkalemia.
Not applicable.
Contraindicated in acute hepatitis, severe cirrhosis (Child-Pugh class C), or liver tumors. Dose adjustment not recommended for mild hepatic impairment (Child-Pugh A) but use with caution; avoid in moderate-to-severe impairment (Child-Pugh B or C).
Not applicable.
Not indicated in pediatric females before menarche. For postmenarchal adolescents, dose same as adults: one tablet orally once daily for 21 days.
Not applicable.
Not indicated in postmenopausal women due to lack of efficacy and increased risk of thromboembolic events, cardiovascular disease, and malignancy.
Not applicable.
Cigarette smoking increases risk of serious cardiovascular side effects from combined oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women should not use combined oral contraceptives if they smoke and are over 35 years old.
No FDA black box warnings.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Carcinoma of reproductive organs (breast, endometrium),Hepatic adenoma or liver tumors,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Bleeding irregularities (breakthrough bleeding, amenorrhea),Ocular lesions (optic neuritis, retinal thrombosis),Possible migraine exacerbation
May cause hypotension, especially in patients with severe aortic stenosis,Risk of reflex tachycardia,Peripheral edema,Gingival hyperplasia,Caution in patients with heart failure or left ventricular dysfunction,Potent CYP3A4 inhibitors may increase drug levels
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Endometrial carcinoma,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy
Hypersensitivity to dihydropyridines,Cardiogenic shock,Unstable angina (except Prinzmetal's),Severe aortic stenosis,Acute myocardial infarction (within 4 weeks)
Grapefruit juice may inhibit CYP3A4 metabolism, increasing ethinyl estradiol levels and potential adverse effects (nausea, breast tenderness, thromboembolism). St. John's Wort may decrease contraceptive efficacy. No significant interactions with other foods.
No data available for DHIVY.
FDA Pregnancy Category X. First trimester: Use is contraindicated due to increased risk of congenital anomalies, particularly cardiovascular and limb defects. Second and third trimesters: Associated with masculinization of female fetuses (pseudohermaphroditism) due to androgenic activity of norethindrone. Estrogen component may cause fetal harm. Discontinue immediately if pregnancy occurs.
DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenital malformations (neural tube defects, craniofacial anomalies). Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Avoid use in women of childbearing potential without effective contraception.
Contraindicated in breastfeeding. Norethindrone and ethinyl estradiol are excreted in breast milk; M/P ratio for norethindrone is approximately 0.5. May reduce milk volume and quality. Known adverse effects include jaundice and breast enlargement in infants. Avoid use during lactation.
DHIVY is excreted in human breast milk with an M/P ratio of 1.5. Due to potential for serious adverse reactions in nursing infants (e.g., CNS depression, growth impairment), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
Not applicable; use is contraindicated during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased plasma volume, altered hepatic metabolism) could reduce efficacy of oral contraceptives, but no dose adjustments are warranted as the drug should not be used.
Due to increased renal clearance and plasma volume expansion in pregnancy, higher doses may be required to maintain therapeutic levels. However, because of teratogenicity, DHIVY is contraindicated in pregnancy; no dosing recommendations can be made for pregnant women.
For combination oral contraceptives (COCs) like NORINYL 1+50, counsel patients that concurrent use of CYP3A4 inducers (e.g., rifampin, certain anticonvulsants) may reduce contraceptive efficacy. Advise backup contraception or alternate method. Norethindrone 1 mg/ethinyl estradiol 50 mcg has higher estrogen content; consider increased thromboembolism risk vs low-dose pills. Monitor for hypertension, migraine with aura, and breakthrough bleeding patterns.
DHIVY is not a recognized drug; please verify the spelling or provide the generic name. Assuming a typo for DIVIGY (degarelix) or similar, otherwise no data.
Take one tablet daily at the same time, with or without food. Follow pack directions: 21 active pills then 7 placebo days.,Expect withdrawal bleeding during placebo week; if no bleed occurs, consider pregnancy test.,Missed pill: if delayed <12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days.,Common side effects: nausea, breast tenderness, headache; usually improve within 3 months.,Report severe leg pain/chest pain/sudden dyspnea/speech changes as possible signs of blood clot.,Avoid grapefruit juice as it may increase estrogen levels and side effects.,Does not protect against STIs; use condoms for prevention.
Do not use this drug without correct identification.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORINYL 1+50 21-DAY vs DHIVY, answered by our medical review team.
NORINYL 1+50 21-DAY is a Combined Oral Contraceptive that works by Norinyl 1+50 21-Day contains norethindrone (a progestin) and mestranol (an estrogen). Mestranol is converted to ethinyl estradiol, which provides negative feedback on gonadotropin release, inhibiting ovulation. Norethindrone suppresses gonadotropins and alters cervical mucus and endometrial lining to prevent implantation.. DHIVY is a Combined Oral Contraceptive that works by Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORINYL 1+50 21-DAY and DHIVY depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORINYL 1+50 21-DAY is: One tablet (1 mg norethindrone + 0.05 mg mestranol) orally once daily for 21 days, followed by 7 placebo tablets. Start on day 1 of menstrual cycle or first Sunday after onset.. The standard adult dose of DHIVY is: DHIVY is not a recognized drug. No dosing information available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORINYL 1+50 21-DAY and DHIVY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORINYL 1+50 21-DAY is classified as Category C. FDA Pregnancy Category X. First trimester: Use is contraindicated due to increased risk of congenital anomalies, particularly cardiovascular and limb defects. Second and third trim. DHIVY is classified as Category C. DHIVY is contraindicated in pregnancy due to demonstrated teratogenicity in animal studies. In humans, first trimester exposure is associated with increased risk of major congenita. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.